Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting
Globe Newswire•04/11/2026•09:00 ET
0
Key Highlights
- ➤DMR-001 showed average 95-fold greater anti-proliferative potency versus reference antibody
- ➤ASH data will cover 10 non-Type 1 CALR mutations, including Type 2
- ➤CLARITY-101 Phase 1/1b trial starts at 100 mg monthly subcutaneous dosing
- ➤Adaptive Bayesian escalation aims to identify recommended dose for Phase 1b expansion
- ➤DMR-001 targets mutCALR-driven ET and MF; no therapies are approved
Expert Statements
Becker Hewes, Chief Medical Officer of Damora Therapeutics
“Previously presented preclinical data combined with new results expected at the ASH Annual Meeting support DMR-001’s potential to set a new bar for pan-mutant activity in mutCALR-driven myeloproliferative neoplasms”
Becker Hewes, Chief Medical Officer of Damora Therapeutics
“At ASH, we will provide insight for the first time on DMR-001’s activity across the breadth of non-Type 1 mutations, including Type 2 and other noncanonical mutations, which together represent nearly half of the overall population with mutCALR-driven disease”
Becker Hewes, Chief Medical Officer of Damora Therapeutics
“These data further strengthen our conviction in DMR-001’s best-in-class potential and reinforce our commitment to rapidly advance ongoing DMR-001 clinical development”
-- Building on previously presented DMR-001 preclinical data in Type 1 and Type 2 CALR mutations, new data to highlight strong activity against additional non-Type 1 mutations --
-- Trial-in-progress presentation to highlight the ongoing CLARITY-101 Phase 1/1b trial of DMR-001 in mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF) --
Get started
Create a free account to read the full story.